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ABSTRACT

ARTICLE HISTORY

Cholangiocarcinoma is a highly morbid gastrointestinal malignancy for which available therapies are
limited. Standard of care includes cytotoxic chemotherapies such as gemcitabine, platinum agents, nabpaclitaxel, and fluoropyrimidine analogues. However, tolerability of these regimens varies, and patients
who do not tolerate chemotherapy have limited targeted therapies and immunotherapy options. In
cholangiocarcinoma, mesenchymal–epithelial transition factor (MET) amplification may present an addi
tional opportunity for a targeted therapeutic approach, especially considering emerging data in non-small
cell lung cancer. In this case, we present a metastatic cholangiocarcinoma patient with high-level MET
gene amplification for whom capmatinib, a tyrosine kinase inhibitor with activity against c-MET, provided
a partial response after cessation of chemotherapy.
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Introduction
Cholangiocarcinoma (CCA) constitutes 3% of all gastrointest
inal tumors and 15% of all liver cancers while carrying a high
mortality rate, accounting for 20% of hepatobiliary cancer
deaths.1 Cholangiocarcinoma is further subdivided based on
anatomical site of origin including intrahepatic (10–20%) and
extrahepatic, both perihilar (50–60%) and distal (20–30%). The
majority of intrahepatic cholangiocarcinoma (iCCA) patients
are diagnosed with advanced disease and are not candidates for
surgical resection. Though the major focus of treatment involves
cytotoxic therapy, performance status may limit the ability for
clinicians to offer treatment as the median age at diagnosis is
approximately 70 years. CCAs are also highly heterogeneous,
often resulting in chemoresistance and poor prognosis.2
Comprehensive genomic profiling has become an essential
tool for discovering personalized treatment options for
advanced cancer patients based on their tumor-specific geno
mic alterations. Pan-tumor approvals of immunotherapies and
targeted therapies for NTRK gene fusions have made them
attractive options for patients who cannot receive conventional
chemotherapy. The KEYNOTE-158 study led to pembrolizu
mab approval in microsatellite instability high (MSI-H) solid
tumors, and activity was successfully demonstrated in MSI-H
CCA.3 However, these only comprise 1.3% of all CCA cases.4
The KEYNOTE-158 study also led to pan-tumor approval of
pembrolizumab for patient tumors identified as Tumor
Mutational Burden (TMB)-High (TMB ≥ 10 mutations/mega
base); however, there were no biliary tract tumors in this study
that were found to be TMB-High.5 Studies leading to the
approval of larotrectinib6 and entrectinib7 for solid tumors
with NTRK fusion alterations also included NTRK fusionpositive CCA patients, though these cases are rare.
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Approximately 50% of CCAs have druggable alterations,
allowing for increased use of targeted therapies in CCA.8
Currently, guidelines include recommendations for use of tar
geted agents in patients with unresectable and metastatic dis
ease after progression on primary treatment.9 This includes
FGFR2 fusions and rearrangements (found in 9–16% of iCCA
cases),8,10,11 IDH1 mutations (16–25%),8,12 and BRAF V600E
mutations (1–6%) (Figure 1).8,13–15 There are a variety of
additional emerging targets in CCA that may lead to new
personalized therapy approaches such as mutations in KRAS
(22–34% of iCCA) and PIK3CA (4–9%) as well as ROS1 rear
rangements (8–9%) (Figure 1).8,15,16
The mesenchymal-epithelial transition factor (c-MET) is
a receptor tyrosine kinase that activates multiple downstream
signaling pathways upon hepatocyte growth factor (HGF) ligand
binding and dimerization including phosphatidyl inositol
3-kinase (PI3K)/AKT, mitogen activated protein kinase and
others.17 MET gene amplification has been found to be oncogenic
and potentially targetable in several solid tumor types including
2% of iCCA cases.16 However, there is limited clinical evidence for
c-MET inhibition in MET amplified CCA patients. A phase II
study investigated the multikinase inhibitor cabozantinib in pre
treated, unselected patients with advanced CCA resulting in lim
ited activity with high toxicity.18 However, one patient considered
to have high MET expression (3+ by immunohistochemical
(IHC) analysis) experienced a prolonged benefit and duration of
treatment. In a phase I study, the c-MET inhibitor tivantinib was
given in combination with gemcitabine in patients with advanced
or metastatic solid tumors including 8 cases of CCA.19 Of the 49
evaluable patients, 39% were strongly positive for MET expression
by IHC. Partial response or stable disease was observed in 20% of
patients including 1 patient with CCA.
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Figure 1. Frequency of actionable and emerging molecular targets & biomarkers in intrahepatic cholangiocarcinoma. (*) indicates NCCN guideline recommended
actionable alterations or biomarkers associated with one or more approved targeted therapies for primary or subsequent-line therapy after disease progression for
unresectable and metastatic biliary tract cancers. MSI-H: microsatellite instability high; TMB-H: tumor mutational burden high defined as ≥10 mutations (mut)/
megabase (Mb).

In the following case study, we describe an older male
patient with iCCA who was unable to tolerate standard of
care cytotoxic therapies. Comprehensive genomic profiling of
this patient’s tumor revealed high MET gene amplification
resulting in the use of capmatinib, a highly potent and selective
inhibitor of the MET receptor.

Case presentation
A 77-year-old man with a history of spinal stenosis presented
to the hospital for planned L4-S1 decompression and fusion.
Following surgery, he was noted to have become jaundiced,
and liver function testing revealed total and direct bilirubin as
6.4 mg/dL and 5.2 mg/dL, respectively. Cross-sectional

imaging was obtained and revealed an infiltrative mass in the
liver measuring 8.3 cm x 4.8 cm x 5.9 cm with associated
intrahepatic biliary dilatation (Figure 2a). There were scattered,
sub-centimeter pulmonary nodules on chest imaging suspi
cious for metastatic disease.
He underwent endoscopic retrograde cholangiopancreato
graphy (ERCP), and two stents were deployed into his right
and left hepatic ducts, respectively. Biliary brushings and CTguided liver biopsy revealed a poorly differentiated adenocar
cinoma supporting a primary diagnosis of iCCA.
Upon interview in the oncology clinic, the only pertinent
family history reported was his mother, with a history of gastric
cancer who was deceased by age 59. The option for genetic
testing was discussed but the patient opted to defer. Further

Figure 2. Infiltrative liver mass at various stages of treatment. (A) liver mass at initial diagnosis; (B) after cytotoxic chemotherapy was stopped due to tolerability, prior to
initiation of capmatinib; and (C) 3 months after initiation of capmatinib.
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history revealed that the patient was a veteran of the Vietnam
War having been exposed to Agent Orange. He worked in the
oil industry later in life. He was a nonsmoker, drank a moderate
amount of alcohol (1–2 standard drinks per day), and had never
used recreational drugs. After determining that he was not
a surgical candidate, he was started on systemic therapy with
gemcitabine, cisplatin, and nab-paclitaxel. Patient experienced
best objective response of stable disease on this regimen.
Over the course of this regimen, treatment delays and dose
reductions were necessary due to the treatment-emergent fati
gue and thrombocytopenia, with a nadir of 55,000 platelets per
microliter. Ultimately, it was decided that these adverse effects
were intolerable, and treatment with cytotoxic chemotherapy
was discontinued after 8 months since treatment initiation.
This prompted comprehensive genomic profiling using
FoundationOne®CDx for consideration of alternate targeted
therapies. Genomic profiling results from the tumor tissue
revealed immunotherapy biomarkers as microsatellite stable
with low TMB (5 mut/Mb), mutations in TERT promoter
and TP53, amplifications of CDK6, CUL4A, and MET, and
equivocal amplifications of FGF14 and IRS2. Of the possible
targets, MET was considered an appealing option due to the
existing literature supporting the use of small molecule tyro
sine kinase inhibitors (TKIs) in MET-amplified tumors. After
discussing available agents, the patient agreed to an empiric
trial of capmatinib, a TKI approved for treatment of non-small
cell lung cancers (NSCLC) that exhibit an exon 14 skipping
mutation in the MET gene.
After a four-week treatment holiday to recover from acute
toxicities, repeat imaging showed growth of the tumor from
8.9 cm x 7.4 cm x 8.4 cm (while still on chemotherapy, image
not shown) to 9.4 cm x 6.9 cm x 9.7 cm (Figure 2b). He was
started on capmatinib 400 mg twice daily and tolerated this
dose well. Interval imaging 3 months later showed a partial
response with decrease in size of the liver mass to 6.0 cm
x 3.9 cm x 7.1 cm (Figure 2c). The dose of capmatinib was
subsequently decreased to 300 mg twice daily due to anorexia
and fatigue, and he continued on therapy for another four
months. Two months later, imaging showed slight increase in
the size of the mass to 8.5 cm x 6.5 cm x 6.6 cm accompanied by
significant tumor necrosis. Approximately, 6 months into ther
apy with capmatinib, he experienced a precipitous decline in
performance status (ECOG 4) due to portal hypertension. He
required frequent paracenteses for nonmalignant ascites, and
he entered hospice 15 months after his initial diagnosis.

Discussion
This case represents an example of a MET-amplified iCCA that
responded to targeted c-MET inhibition. The patient was diag
nosed with an inoperable iCCA and was unable to tolerate
conventional cytotoxic chemotherapies. Therefore, he was con
sidered for targeted agents after comprehensive genomic pro
filing of his tumor. Following initiation of the c-MET inhibitor
capmatinib, he enjoyed a partial response and nearly six
months of improved quality of life.
One of the difficulties in clinical practice is choosing which
molecular aberration to target with subsequent-line therapy
once standard of care, guideline-directed treatment becomes

unfeasible. With the exception of a mutation in TP53, most of
the genomic alterations detected in this patient’s tumor are not
common in iCCA, nor are they associated with approved
targeted agents in CCA or other solid tumors. However, the
MET gene amplification was particularly notable in this case,
considering the recent approval of the c-MET tyrosine kinase
inhibitor capmatinib for NSCLC patients based on results from
the GEOMETRY mono-1 trial.20 This phase 2 trial described
the use of capmatinib in NSCLC patients whose tumors har
bored MET exon 14 skipping mutations or were METamplified. In this study, MET gene copy number (GCN) was
assessed in tumor tissue by next generation sequencing. In
patients with MET amplification GCN < 10, ORR was 7–12%.
However, those with a GCN of 10 or higher showed an ORR of
29% in previously treated patients and 40% in treatment naïve
patients with a median duration of response of around 8
months and median progression free survival (PFS) of just
over 4 months.
It is worth noting that detection methods and cutoffs for
high-level versus low-level MET gene amplification are not
standardized. Studies in multiple malignancies, both clinical
and preclinical, define the GCN cutoff at varying levels between
4 and 10.20–22 In this case, MET gene amplification in this
patient’s tumor was at a GCN of 23. Despite some categorical
uncertainty in the broader medical literature, this GCN was
considered to be highly amplified, as defined by the
GEOMETRY trial, and was considered an appropriate focus
for targeted therapy.
A poorer prognosis is evident in numerous cancers, includ
ing CCAs, which exhibit high expression of c-MET.17,23 In
addition, MET mutations and amplifications have been asso
ciated with drug resistance in multiple cancer types. Therefore,
targeting c-MET is of acute scientific and clinical interest in
MET-amplified malignancies. Few clinical data exist to support
inhibition of c-MET as a standalone therapy, but there is
a growing evidence base given the increasing availability of
these agents. For example, a 2021 report of results from the
AcSé-crizotinib program indicated a role for c-MET inhibition
in MET-amplified esophageal and gastric cancers. Nine
patients with chemotherapy-refractory tumors having
≥6 MET copies were treated with crizotinib monotherapy
demonstrating an ORR of 33.3%, median PFS of 3.2 months,
and overall survival of 8.1 months.24
Previous and ongoing studies provide some generalizable
evidence for the use of c-MET-directed agents in METamplified tumors. There are currently an abundance of clinical
trials studying selective and nonselective c-MET inhibitors
alone or in combination with other therapies across many
cancers with MET mutations or amplification.17 There are
currently no ongoing clinical trials specifically targeting
c-MET positive CCA, though these patients may be eligible
to enter any trial investigating these agents in all solid tumors.
With such limited clinical data available, it is hard to draw firm
conclusions about the use of these agents in CCA. More clinical
trials investigating c-MET specific targeted therapies in CCA
patients with MET-amplification are warranted. Nevertheless,
the foundational science supports the role for c-MET inhibi
tion in MET amplified CCA, and this case represents one
instance in which a patient benefited from such therapy.
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Conclusions
Comprehensive genomic profiling is crucial for treatment deci
sions in patients with metastatic cancers, providing clinicians the
information to choose appropriate therapeutic options and enroll
patients in clinical trials. This is especially important when con
sidering tumor types where standard of care therapies are limited.
In this report, we discussed a patient with advanced CCA who
was found to have high-level MET gene amplification. Because of
strong evidence in MET-amplified NSCLC in the GEOMETRY
mono-1 trial, capmatinib was chosen as subsequent-line therapy
after the patient was unable to tolerate cytotoxic chemotherapy.
He was found to have a partial response and enjoyed six months
of improved quality of life before ultimately experiencing com
plications of progressive disease and enrolling in hospice.
This case may indicate that c-MET inhibition is a reasonable
consideration in patients with MET-amplified cholangiocarci
noma in whom cytotoxic therapy is no longer an option.
Further, randomized studies should be performed in this popu
lation in order to define the role for these agents, which may
provide benefit beyond available therapies.
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